Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Fentanyl Sublingual Spray in Opioid Naive Subjects
NCT02641340Phase 1Completed
- Sponsor
- Insys Therapeutics
- Start
- Jan 2016
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fentanyl (transdermal patch + oral transmucosal lozenge) in pain (12 cohorts), sponsored by Insys Therapeutics. Primary endpoints: Maximum concentration at 24 hours, Time to reach peak or maximum concentration at 24 hours and 7 more. Started Jan 2016; status: completed.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)
03
Conditions
pain
Beyond the preview
Go deeper on NCT02641340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641340.